Ironwood Pharmaceuticals IRWD Debt-to-equity

Debt-to-equity at other companies

ArdelyxARDX

1.7×+0.2×

Rigel PharmaceuticalsRIGL

0.2×+0.1×

Mirum Pharmaceuticals, Inc.MIRM

0.1×0.0×

Ionis PharmaceuticalsIONS

0.6×-0.7×

Neurocrine BiosciencesNBIX

0.1×-0.1×

Rhythm Pharmaceuticals, Inc.RYTM

0.9×-5.1×

FAQ

What is Ironwood Pharmaceuticals's debt-to-equity?

Ironwood Pharmaceuticals (IRWD) reported debt-to-equity of 0× in Q1 2023.

How has Ironwood Pharmaceuticals's debt-to-equity changed year-over-year?

Ironwood Pharmaceuticals's debt-to-equity decreased by 94.7% year-over-year, from 0.5× to 0×.

What is the long-term trend for Ironwood Pharmaceuticals's debt-to-equity?

Over 2 years (2020 to 2022), Ironwood Pharmaceuticals's debt-to-equity has grown at a -71.6% compound annual growth rate (CAGR), from 0.4× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.